Trading Advice for Arcturus Therapeutics Holdings Inc. ARCT including day trading swing trading and long term investing plans ...

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of directors since June 2024. Published first on TheFly ...

The company's pipeline includes ARCT-810, a treatment for ornithine transcarbamylase deficiency in Phase 2 trials, ARCT-154, a COVID-19 vaccine candidate in Phase 3 trials in Vietnam, and ARCT-032 ...

SAN DIEGO, February 04, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy recommendation. Analyst Price Forecast Suggests 331.48% Upside As of ...

ARCT has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on ...

Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on ARCT stock, giving a Buy rating on January 13. Discover outperforming stocks and invest smarter with Top ...